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Abstract
Magnetic nanoparticles (MNPs) are capable of generate heating power under the influence of alternating magnetic fields
(AMF); this behaviour recently opened new scenarios for advanced biomedical applications, mainly as new promising tumor
therapies. In this paper we have tested magnetic nanoparticles called magnetosomes (MNs): a class of MNPs naturally
produced by magnetotactic bacteria. We extracted MNs from Magnetospirillum gryphiswaldense strain MSR-1 and tested the
interaction with cellular elements and anti-neoplastic activity both in vitro and in vivo, with the aim of developing new
therapeutic approaches for neoplastic diseases. In vitro experiments performed on Human Colon Carcinoma HT-29 cell
cultures demonstrated a strong uptake of MNs with no evident signs of cytotoxicity and revealed three phases in the
interaction: adherence, transport and accumulation in Golgi vesicles. In vivo studies were performed on subcutaneous
tumors in mice; in this model MNs are administered by direct injection in the tumor volume, then a protocol consisting of
three exposures to an AMF rated at 187 kHz and 23kA/m is carried out on alternate days, over a week. Tumors were
monitored by Magnetic Resonance Imaging (MRI) to obtain information about MNs distribution and possible tissue
modifications induced by hyperthermia. Histological analysis showed fibrous and necrotic areas close to MNs injection sites
in mice subjected to a complete thermotherapy protocol. These results, although concerning a specific tumor model, could
be useful to further investigate the feasibility and efficacy of protocols based on MFH. Magnetic nanoparticles naturally
produced and extracted from bacteria seem to be promising candidates for theranostic applications in cancer therapy.
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Introduction
Thermotherapy represents an effective tool for the treatment of
many types of tumor but it is strongly hampered by poor specificity
of the induced lesion [1,2,3]. Several approaches have been
proposed to improve the efficacy of the technique: one of them is
based on intratumoral delivery of magnetic nanoparticles (MNPs)
followed by application of alternating magnetic fields (AMF) to
increase the local temperature of the tissue thus the effectiveness of
the method [3,4,5]. This approach is called magnetic fluid
hyperthermia (MFH).
In 1963, the Italian scientist Salvatore Bellini reported the first
description of magnetotactic bacteria. This subtype of organisms
naturally produces magnetic iron-oxide nanoparticles and uses
them as a compass for geomagnetic navigation to search for
optimal growth conditions [6,7]; those nanoparticles have been
over time referred as magnetosomes (MNs). A more complete
description of magnetotactic bacteria was later reported [8].
Recently, MNs have been proposed as active agents in
hyperthermia for cancer therapy [9,10]; moreover, MNs extracted
from magnetotactic bacteria [11,12] are considered with increas-
ing interest as therapeutic and diagnostic agents mainly because of
their physical properties. It has been reported that, for an applied
AMF of frequency and strength kept below the tolerance threshold
limit of about 200 kHz and 100 mT respectively, the specific
absorption rate (SAR) of the chemically synthesized nanoparticles,
currently used in magnetic thermotherapy, is several orders of
magnitude lower than the one of the biologically synthesized
magnetosomes [9,10-13]. Due to their magnetic properties, MNs
also show high transversal relaxivity [14], a feature that makes
these MNPs highly efficient contrast agents for magnetic
resonance imaging (MRI).
The bacterial strain considered in the present investigation, M.
gryphiswaldense, is able to internalize iron in ionic state from the
environment and to synthesize iron oxide nanoparticles (size range
35-50 nm) of cubic-octahedral shape [15,16]. This biological
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process is extremely repeatable with a very low variance in terms
of size and shape of resulting nanoparticles.
As mentioned before, MNs isolated from magnetotactic bacteria
develop a high heating effect when exposed to AMF. Preliminary
studies prove the possibility of using these MNs as therapeutic
agents when delivered in tumors [4,10].
However, data on the therapeutic effect and biological
interaction of MNs with living tissues are still scarce, and their
toxicity has not been definitively assessed [17]; moreover,
ultrastructural studies on the localization of nanoparticles in the
intracellular compartments are absent [16-18].
In the present study, the interaction of MNs extracted from M.
gryphiswaldense with tumor cells was investigated by using Human
Colon Carcinoma cells (HT-29). Hyperthermia treatment of
colorectal cancer is of particular interest for potential clinical
applications: for this purpose we used a protocol that include
molecular biology, histology, electron microscopy analysis and
magnetic resonance imaging.
The interaction of MNs with tumor cells and their therapeutic
potential was also investigated in vivo in nude mice. In order to
assess the potential usefulness of MNs in magnetic thermotherapy,
we monitored, by MRI an experimental model of colon carcinoma
before and after the treatment with thermotherapy.
Materials and Methods
In vivo experiments: experimental design and
thermotherapy protocol
Twenty-two nude homozygote male mice (Harlan Laboratories,
Udine, Italy) were maintained under standard environmental
conditions (temperature, humidity, 12 h/12 h light/dark cycle,
with water and food ad libitum) under veterinarian assistance.
Animals handling and surgery were performed following a
protocol approved by the Animal Care and Use Committee of
the University of Verona (CIRSAL), and by the Italian Ministry of
Health, in strict adherence to the European Communities Council
(86/609/EEC) directives, minimizing the number of animals used
and avoiding their suffering.
In a preliminary study on a limited number of animals, one
million HT-29 cells, resuspended in 200 ml of sterile PBS, were
subcutaneously injected in the right flank of anesthetized mice.
Ten days after inoculation of tumor cells, mice were monitored by
MRI to measure the tumor size: animals whose tumor volumes
ranged between 0.4 and 0.5 cm3 were injected with MNs. We
observed that usually it was possible to inject a total volume of
about 200 ml by using 3 to 4 separate punctures without relevant
leakage of fluid from the tumor mass. These findings were then
used to design the experimental protocol.
A population of n = 22 mice was divided in two groups: control
and experimental. The control group (n= 12) was further divided
in three subgroups: the first subgroup (n= 4) was administered
with 1 mg of MNs diluted in 200 ml of PBS and did not receive
AMF exposure. Administration of MNs was performed by direct
injection into the tumor mass using an intradermal needle (21G).
The second subgroup (n= 4) was exposed to AMF without MNs
administration. The third subgroup (n= 4) did receive neither
thermotherapy nor MNs administration.
The experimental group (n = 10) received 1 mg of MNs diluted
in 200 ml of PBS and was exposed to AMF on day 0 (immediately
after injection), 2 and 4. The AMF apparatus yield a magnetic
field of intensity 23 kA/m (,29 mT) with a frequency of 187 kHz.
These values are very close to those used in human application of
hyperthermia [19]. Mice were placed on a custom made animal
holder under isofluorane anesthesia 1.5% (Forane, Abbott) and
exposed to AMF for 20 min. A digital IR camera (Flir I7, Flir
Systems, Italy) was used by the operator to record maps of heating
distribution in the tumor and surrounding tissues.
All the mice were monitored by MRI at three time points: 24 h,
one week and two weeks after MNs administration. The first and
second points were chosen to evaluate the physiological distribu-
tion of MNs and acute effects induced by MFH inside the
neoplastic mass, respectively. The last point was useful to check
whether some kinds of alterations do occur after the treatment.
Animals were then sacrificed and tumors excised for histological
analysis. Three mice died during the first steps of the treatment,
probably due to an overdose of anesthetic. Mice were sacrificed by
isofluorane overdose and successively by neck dislocation. These
methods were performed in according to D.L. 4 March 2014 nu26
of the Italian Ministry of Health.
Magnetospirillum gryphiswaldense culture
M. gryphiswaldense MSR-1 (DSM6361) purchased from
Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH (Germany) was cultured in specific growth medium
(optimized during the present study) containing 0.1 g KH2PO4,
0.15 g MgSO4*7H2O, 2.38 g HEPES, 0.34 g NaNO3, 0.1 g yeast
extract, 3 g soy bean peptone, and 1 ml EDTA-chelated trace
element mixture. The medium contained also 27 mM potassium l-
lactate as carbon source and 100 mM of ferric citrate as iron source
[20]. A single colony of MSR-1 from agar plates was transferred to
a tube containing 10 ml of liquid medium and grown with
100 rpm shaking at 28uC for 24 h. This inoculum was grown by
four escalating volume transfers at a ratio of 10% (v/v) before
being used as inoculum in a 5 L screw cap bottle culture. Culture
was maintained at 28uC and agitated at 100 rpm for 24 h.
Purification of MNs
The purification of MNs was performed according to the
protocol proposed by Grunberg [20] as follows: 1) lyses of 10 g of
M. gryphiswaldense dry weight with 50 ml of 50 mM HEPES
4 mM EDTA (pH 7.4) using French-press (1.26 Kbar); 2)
centrifugation at 680 g for 5 min to remove non lysated materials;
3) magnetic separation with magnetic column (MACS, Miltenyi
Biotec); 4) MNs were eluted with 10 mM HEPES (pH 7.4),
positioned on a scaffold of sucrose (55% w/w in 10 mM HEPES),
MNs were centrifuged at 280,000 g for 12 h at 4uC and the pellet
was incubated with 10 mM HEPES for 16 h at 4uC to allow for
solubilization. After purification, MNs were dried for 5 h using a
lyophilizer, irradiated with c-rays (56 Gy for 84 min) and finally
stored at -20uC.
Transmission electron microscopy (TEM)
Whole mount bacteria of different samples of MNs, extracted
and purified, were fixed with glutharaldehyde 2% in Sorensen
buffer pH 7.4 for 2 h, post-fixed in 1% osmium tetroxide in
aqueous solution for 2 h, dehydrated in graded concentrations of
acetone. At the end of dehydrating process, samples were
positioned in a multi-well grid for electron microscopy and
observed using an EM10 electron microscope (Zeiss, Oberkocken,
Germany).
Scanning electron microscopy (SEM)
Specimens were fixed with glutharaldehyde 2% in 0.1 M
buffered phosphate, dehydrated in graded ethanol, critical point
dried (CPD 030, Balzers, Vaduz, Liechtenstein), fixed to stubs with
carbon-based adhesive, sputtered with carbon by MED 010 coater
(Balzers), and examined with an XL30 ESEM scanning electron
Theranostics Magnetic Nanoparticles
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microscope (FEI Company, Eindhoven, Netherlands) equipped for
Energy Dispersion Analysis of X-Ray (EDAX).
Dynamic light scattering (DLS)
Hydrodynamic radius of MNs was determined from a batch of
0,5 mg resuspended in 5 ml of HEPES 10 mM, ultrasonicated for
10 min and filtered using a 450 nm filter. DLS data were obtained
using a He-NE 633 nm wavelength laser with a goniometric set of
173u (Malvern Instrument LTD, UK), normalized to unity and
reported in logarithmic scale.
Susceptibility measurements
Magnetic measurements were carried out on powders (total
MNs weight = 3.6 mg) using a Quantum Design SQUID MPMS
XL-7 magnetometer. The zero field-cooled and field-cooled
(ZFC/FC) magnetization curves were obtained for different
applied magnetic fields in the temperature range 2–300 K, while
the field dependent magnetization measurements were recorded in
the range of 65 T at both 2 K and room temperature.
Thermal properties of MNs
A sample containing 6.7 mg of purified, sterilized and
lyophilized MNs was exposed to an AMF (187 kHz, 23 KA/m
[,29 mT]) for 24 min. The increment of temperature was
measured by an infrared camera Flir i7 (Flir System Inc., Italy).
MNs were then diluted in distilled water at concentration of: 3
mg/ml, 2 mg/ml, 1 mg/ml, 0.5 mg/ml and exposed to AMF
using the same frequency and field strength. In order to estimate
the iron content of our nanoparticles, 4 mg of extracted MNs were
dispersed in a 1:3 mixture of H2SO4 and HNO3 and digested
using a microwave digestor. The preparation was analyzed by
Atomic Adsorption Spectroscopy (AAS, Perkin-Elmer 1100B).
Cancer cells culture
Human Colon Carcinoma cells (HT-29) purchased by ATCC
(Manassas, VA), were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) with 10% of Fetal Bovine Serum (FBS) and 1%
of a mix of penicillin/streptomycin 1:1, in 25 cm2 plates and
incubated at 37uC in humidified air with 5% CO2. Medium,
serum and antibiotic mix were purchased by GIBCO, Life
Technologies, USA. When at confluence, cells were treated with
trypsin-EDTA 1% (GIBCO, Life Technologies, USA), harvested
and centrifuged at 1200 rpm for 5 min. The supernatant was
discarded and cells pellet was resuspended in 1 ml of complete
medium, placed in 75 cm2 plates and incubated at 37uC and 5%
of CO2 until 80% confluence was detectable.
In vitro MTT test
The cytotoxicity of MNs versus HT-29 cells was assessed by the
loss of cells viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) (MTT) test. Cells were plated at a density
of 8*103 cells per well in 96-well plates and incubated at 37uC in a
mixture of air and 5% CO2. After 24 h, the medium was replaced
with fresh medium containing 1, 0.5 and 0.2 mg/ml of sterilized
MNs, respectively. After 6, 12 and 24 h of incubation, 10 ml of
MTT solution (Sigma, Italy) was added to each well. Plates were
then incubated for additional 4 h (37uC, 5% CO2). After the
incubation time, plates were removed from the incubator and
formazan crystals formed by the living cells were dissolved in
100 ml of dimethyl sulfoxide (Sigma, Italy). The multiwell was
placed into a microplate reader (CHROMATE 4300 Awareness
Technology, USA) for the measurement of absorbance at 570 and
630 nm. Four measurements of optical density (OD) were
recorded for each sample and cell viability (%) was calculated
with the following equation: CV%= (ODsample/ODcontrol) N 100.
In vitro assay of MNs-uptake in cancer cells
A plate containing 2*105 cells was placed in specific glasses
multiwell for optical microscopy (Falcon BD, Italy) with 1 ml of
growth medium. Cells were incubated at 37uC in humidified air
with 5% CO2 for 24 h. The growth medium was then discarded
and replaced with fresh medium added with MNs at different
concentrations: 1 mg/ml, 0.5 mg/ml, 0.2 mg/ml. Cells were
incubated as previously described for 6 h, 12 h and 24 h. At each
time point, the growth medium was discarded and cells were
washed with 1 ml of 1X sterile phosphate buffer saline (PBS,
GIBCO, Life Technologies, USA). Cells were fixed with 1 ml of
4% buffered formalin (Bioptica, Italy) for 30 min at room
temperature. Once formalin was discarded, cells were double
stained: Prussian Blue to visualize MNs and Nuclear Fast Red
(Bioptica, Italy) to visualize nuclei. HT-29 samples were observed
at 10X, 20X and 40X optical magnification using an Olympus
microscope (BX-URA2, Olympus optical, GMBH, Hamburg,
Germany) equipped with Image ProPlus software (Media Cyber-
netics, Rockville, USA).
TEM of cells incubated with MNs
HT-29 cancer cells were plated on a 2.4 cm culture glass,
positioned on the bottom of 3.5 cm Petri dishes and incubated at
37uC in humidified air with 5% of CO2 in 3 ml of growth
medium. After 24 h, cells were fixed with glutaraldehyde 2% in
Sorensen buffer pH 7.4 for 2 h, then post-fixed in 1% osmium
tetroxide (OsO4) in aqueous solution for 2 h, and finally
dehydrated in graded concentrations of acetone. At the end of
dehydrating process, glasses were stained with lead citrate and
observed using a XL30 ESEM scanning electron microscope (FEI
Company, Eindhoven, Netherlands).
MRI
MR images were acquired in order to monitor the tumor
growth at days 1, 7 and 14 both for control and experimental
groups. MRI was performed using a Bruker tomograph operating
at 4.7 T, equipped with an actively shielded gradient insert
(Bruker, Germany) having a maximum gradient strength of 40 G/
cm. Animals were placed prone in a heated bed and a 3.5 cm i.d.
birdcage coil was used to acquire the MR signal. T2 and T2*
weighted images were acquired to detect the tumor and the
presence of MNs respectively. T2weighted images were acquired
using a RARE 3D sequence with TR =1200 ms, TEeff = 47.5 ms,
FOV=562.562.5 cm3, NEX =1, MTX =256/128/32, Slice
Thickness = 0.78 mm. T2*weighted images were acquired using a
FLASH gradient echo sequence with TR =400 ms, TE = 4.4ms,
flip angle = 10u, FOV =562.5 cm, NEX =2, MTX =256/128,
NSLICES = 8, Slice Thickness = 2 mm.
Histology
After the last MRI acquisition, animals were sacrificed and
tumors were excised, washed with PBS 0.1 M and fixed with 10%
buffered formalin for 4 h. Afterwards, samples were dehydrated
with increasing concentration gradient of alcohol from 70% to
100% and then with xylene for final processing. Tissues were
embedded in paraffin and sections of 5 mm were obtained and
dried at 37uC for 24 h. Sections were stained with Prussian blue
and Nuclear Fast Red (Bioptica) to visualize iron nanoparticles
and nuclei respectively.
Theranostics Magnetic Nanoparticles
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Results
Morphology and physical properties of MNs
TEM of whole-mount bacteria, observed by backscattered
electron detector, showed that MNs are organized in long chains
(Figure 1a) along the major axis of each bacterium. Figure 1b
and 1c show TEM images of MNs extracted from M.
gryphiswaldense. The cubic-octahedral structure of crystals (mean
Feret’s diameter of iron core = 4269 nm) and the surrounding
membrane (see arrows in Figure 1c) are clearly visible. AAS
reported an iron content 0.167 mg Fe/g of extracted MNs, EDAX
spectrum showed the absence of any metal except iron
(Figure 1d).
A temperature increment of about 10uC was obtained in
lyophilized MNs sample (6.7 mg) upon application of AMF for
24 min (Figure 2a). The increment of temperature consistently
decreased with the concentration of MNs diluted in distilled water.
Such enhancement amounted to about 5uC for a sample
containing 3 mg/ml of MNs, to about 3uC for the sample
containing 2 mg/ml and to about 2uC for the sample containing 1
mg/ml of MNs. The less concentrated sample, with 0.5 mg/ml of
MNs, gained an increment of 1uC (Figure 2b).
The magnetic measurements of MNs revealed, as expected, a
single-domain superparamagnetic-like behaviour with almost
closed hysteresis at room temperature (Figure 3a) and irrevers-
ibility effect in ZFC/FC curves. The saturation magnetization, Ms
,40 emu/g, is compatible with values commonly reported for
magnetosomes [13] and iron oxide nanoparticles in general. From
the ZFC curve maximum displayed at low applied magnetic field
(Figure 3b), the superparamagnetic blocking temperature is
estimated to be TB ,300 K or higher. In addition, a discontinuity
in the magnetization curves as a function of temperature can be
clearly seen at around 110 K (Figure 3b). This is possibly an
evidence of the Verwey transition, a long range charge re-
arrangement that occurs mainly in transition metal oxides; such
transition is also a signature for the existence of magnetite phase
[21].
DLS
The distribution of the mean hydrodynamic radius shows a
peak centered at 225 nm; this value is in good agreement with
other data obtained on magnetosomes [22,23]. A second peak,
centered around 40 nm can be attributed to small single
nanoparticles (Figure 4).
Figure 1. TEM of MNs. Panel a shows the organization of MNs in chains in the bacteria (scale bar, 500 nm). Panels b-c show that the typical
conformation of chains is maintained after isolation of MNs. Scale bars: b.200 nm, c.100 nm. Panel d, X-ray microanalysis shows the iron content of
the MNs.
doi:10.1371/journal.pone.0108959.g001
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In vitro uptake of MNs in HT-29 cancer cells
Prussian Blue staining demonstrated a strong uptake of iron
nanoparticles by HT-29 cells as clearly depicted in Figure 5.
MNs were detected primarily on the cell membrane although
some were also visible within cytoplasm. The effect of varying
MNs concentration in the culture medium and incubation time
was investigated. Qualitative analysis of stained samples showed
that, among the different concentrations tested (ranging from 0.2
to 1 mg/ml), the best condition for a good internalization was 0.2
mg/ml of MNs; the most effective time of incubation, with purified
and sterilized MNs, was 24 h. Despite the high level of iron
internalization, detectable changes of phenotype were not
appreciable. (Figure 5b-d).
The internalization process of MNs was deeply investigated by
TEM: representative images are reported in Figure 6. At least
three kinds of interaction were found, likely corresponding to three
different internalization steps. In the first step MNs were adherent
to the cell membrane, with the formation of invaginations
surrounding MNs chains (Figure6 1b). In the second step
(Figure 6 2b), MNs were located into the cytoplasm, enclosed in
vesicles. In the third step (Figure 6 3b), MNs were found into the
Golgi apparatus and specifically into the innermost vesicles. In
each of these steps, MNs were detectable as isolated particles, as
small groups or short chains (Figure 6 a,b). MNs were found in
vesicular formations similar to lysosomes presumably excreted
from the Golgi apparatus. In some cases, these formations had a
multi-vesicular aspect, while in others they appeared filled with
material similar to multilamellar phospholipids. TEM images
performed on HT-29 cancer cells showed the presence of chains of
MNs in the cytoplasm, confirming the internalization process and
the stability of the chain structure (Figure 6c).
SEM images did not show any appreciable alteration of the
cellular surface in comparison to the controls (Figure 6d).
MTT test
MTT assay revealed that different amounts of sterilized MNs (1
mg/ml, 0.5 mg/ml, 0.2 mg/ml), when incubated for varying time
periods with HT-29 cells, do not show statistically significant
Figure 2. Thermal properties of MNs in alternate magnetic field. Variation of temperature of samples containing: (a) 6.7 mg of MNs
lyophilized and (b) MNs diluted in distilled water at concentration of: 3 mg/ml, 2 mg/ml, 1 mg/ml, 0.5 mg/ml exposed to an AMF of 187 kHz (23kA/m)
as a function of time, measured by infrared camera.
doi:10.1371/journal.pone.0108959.g002
Figure 3. Susceptibility measurement. DC susceptibility measurements performed on a freeze-dried magnetosomes sample: (a) hysteresis loops
at high (300 K) and low (2 K) temperature and (b) Zero Field-Cooled/Field-Cooled (ZFC/FC) curves collected at low field, H= 50 Oe.
doi:10.1371/journal.pone.0108959.g003
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negative effects (one way ANOVA, p.0.05) on cell viability at any
dosage. The results are reported in Figure 7.
In vivo experiments
Thermal images were acquired in each mouse during the
exposure to AMF by using an infrared camera. Temperature
increments ranging between 2 and 3uC were observed in tumors
treated with MNs. On the other side, negligible variations of
thermal maps were recorded in tumors exposed to AMF that did
not receive MNs injection.
MR images were acquired to monitor the development of tumor
mass before and after hyperthermia treatment: as reported in
Figure 8, several regions of strong signal drop are clearly visible.
In T2-weighted images, most of the neoplastic parenchyma was
iso-intense. In the first subgroup of control group (Figure 8A a-d,
white stars), the injection of MNs was clearly detectable and
MRI showed areas of signal drop due to the presence of iron in the
injection site. No other relevant changes were detectable in the
signal intensity of the tumor parenchyma. This strong, negative
enhancement, common to iron-based nanoparticles [24,25], sets
the basis for potential application of MNs as negative contrast
agents in MRI. This feature has relevance in the possible
translation of these methods to the clinics for theranostics
applications. Mice in the second subgroup of control group
(Figure 8B i-m) showed moderate increase of signal intensity in
small regions of the tumor, probably due to edema associated to
necrosis caused by fast tumor growth. In the third subgroup of the
control group (Figure 8B n), tumor appeared as a well defined
mass with sharp boundaries, located in subcutaneous tissue (see
arrow). Furthermore, a thin hyperintense layer was detectable at
Figure 4. Dynamic Ligth Scattering. Scattered light intensity weighted magnetosomes size distribution in ultrasonicated and filtered HEPES
solution; the two peaks centered at 225 nm and 40 nm are in good agreement with the size of chains of magnetosomes and single nanoparticles,
respectively.
doi:10.1371/journal.pone.0108959.g004
Figure 5. Cancer cell culture. The figure shows the untreated cells
(a) and MNs-treated cells (b-d) observed after 24 h. Prussian Blue
evidences the iron depots. Enlargement: a.50 mm, b.10 mm, c.
10 mm and d.10 mm.
doi:10.1371/journal.pone.0108959.g005
Figure 6. TEM shows the internalization of chains of MNs in HT-
29 cancer cells. The chains that have penetrated in the cells are
composed by 6-10 units of MNs and are positioned near the nucleus
(Panel a). In Panel b, MNs are visible at cell membrane (arrows) or in the
Golgi complex. Panel c shows the localization of the MNs in cytoplasmic
vacuoles at high enlargement (Scale bars, a 2 mm, b 1 mm, c 120 nm, d
10 mm). Panel d shows a representative SEM image of HT-29 cancer cell
(0.2 mg/ml MNs 12 h); no appreciable alterations of the surface are
visible when compared to controls.
doi:10.1371/journal.pone.0108959.g006
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the edges of the tumor (Figure 8B n). Areas of high intensity were
detectable and attributable to edema. In the central portion of the
tumor, areas of low signal intensity, that could be identified as
necrotic or hemorrhagic sites, were observable (see arrow). In the
experimental group (Figure 8A e-h), tumors appeared as non-
homogeneous masses characterized by regions of moderate loss of
signal (probably corresponding to necrosis, see arrows), while areas
with a higher loss of signal represent regions of MNs diffusion
(white stars in Figure 8A g, h). Compared to the control group
(third subgroup, Figure 8B n), there was an increment of both
the edematous (hyperintense) and necrotic/hemorrhagic (hypoin-
tense) components. In some cases, these degenerative aspects were
prominent in correspondence to the injection site.
MR images performed after a complete thermotherapy protocol
(Figure 8Ag ), did not show significant differences in signal
intensity when compared to images acquired 24 h after MNs
injection (white stars, Figure 8A f).
Histology
Histological examinations contributed in elucidating the effect
of different treatments. Sections obtained from tumors treated with
MNs and thermotherapy showed clear evidence of edematous and
necrotic phenomena that were not evident in corresponding
sections extracted from the control group (Figure 9 A-C). The
injection site of MNs was clearly visible (white star, Figure 9A)
and is characterized by degenerating unclustered cells intruded by
extracellular matrix. Evidences of necrosis and fibrosis, induced by
temperature enhancement, were significantly spread and detect-
able also in regions away from the site of injection (white star,
Figure 9C). Tumors treated only with MNs (first subgroup,
Figure 9 D-F) did not show appreciable differences compared to
those of the second subgroup; in these tumors the site of injection
was highlighted by histochemical staining. Iron nanoparticles
marked with Prussian Blue staining were detected in subcutaneous
areas and within the tumor mainly along the connective tissue
septa or in perivascular locations. There, elongated cellular
elements showing a marked uptake of MNs were present and
possibly identifiable as macrophages (Figure 9, D-F). Tumors
belonging to the third subgroup (Figure 9, L-N) were character-
ized by the presence of a thin connective capsule surrounded by a
layer of adipose tissue, with some connective branches infiltrating
the neoplastic mass. Tumor tissue showed the typical features of
epithelial tumors: a solid mass with a high nucleo-cytoplasmatic
ratio arranged in nests. Isolated areas of edema, necrosis or
hemorrhage were visible usually in the central portion of the
histological sample. Tumors of the second subgroup did not shown
marked differences compared to those of the third subgroup with
the exception of a moderate increase in edematous or necrotic
components (Figure 9, G-I).
Concerning the persistence of the MNs, histological examina-
tions performed two weeks after administration revealed the
presence of MNPs next to the injection site, with spots also
detectable in the surrounding parenchyma.
Discussion
A renewed interest in biomedical applications of MNPs has
increased considerably over the past years, with MNs attracting
widespread attention because of their prospective medical
applications either as contrast agents for MRI, as heating
mediators for cancer therapy by intracellular hyperthermia or as
drug delivery carrier [14,26,27,28]. The efficiency of MNs as
heating mediators is strongly dependent on the interaction with
cells and the capability to cross the phospholipid membrane [29].
Recent studies on cancer proposed a new potential role of MNs
as ‘‘theranostics’’ agents. The therapeutic efficacy of MNPs on
mouse mammary carcinoma, glioblastoma, and prostate cancer
demonstrated the feasibility and efficacy of this heating method, as
well as a very low clearance rate of these nanoparticles from
tumors, allowing for longitudinal treatment following a single
magnetic fluid injection [3,30]. MNPs have been used in clinical
trials with prostate cancer [4] and glioblastoma multiforme [2].
Although these studies proved that thermotherapy of tumors using
MNPs can be safely applied, studies on the biological interaction
between cells and MNPs are still poor.
The aim of this study was to analyze the interaction, both in
vitro and in vivo, of tumor cells with MNs extracted from a strain
of magnetotactic bacteria. Among different strains, we chose M.
gryphiswaldense for its availability and lack of knowledge about its
biological interaction with cells. TEM images on bacteria and
isolated nanoparticles confirmed the cubic-octahedric shape and
the organization in chains; DLS data, obtained on an homoge-
neous solution, showed the presence of clusters of about five
elements along with a small number of single MNs. Some
researches focused on chains length suggesting a relation between
Figure 7. MTT assay on HT-29 cells after uptake with MNs. MTT assay shows a negligible cytotoxic effect of MNs: percent viability of cells
incubated with MNs is expressed relevant to control cells.
doi:10.1371/journal.pone.0108959.g007
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this parameter and the thermal properties of MNs. Our findings
on ultrastructural analysis show that even though MNs extracted
from bacteria are actually organized in chains of several elements
as previously reported [10], they enter the intracellular space as
single nanoparticles or as short chains.
Due to intrinsic limitations of standard histology, the interaction
between MNs and tumor cells was investigated at a higher spatial
resolution by electron microscopy. TEM images suggested a
determined multistep pathway of MNs internalization. After
adhesion to the phospholipid membrane, MNs were enclosed in
vesicles, carried near the Golgi apparatus and finally included in
vesicles that resemble a double layered membrane.
It is well known the high sensitivity of tumor cells to thermal
variation. Temperatures ranging between 42 and 47uC degrees
cause degenerative processes in neoplastic cells [25]. We tested
thermal properties of MNs from M. gryphiswaldense included in a
tumor mass with a protocol based on hyperthermia induced by an
AMF and the reaction of the xenograft neoplasm was observed by
MRI and histology. Contrary to what previously reported [9], in
none of the animals belonging to the experimental group a
complete remission of the tumor after the treatment was obtained.
The lower AMF strength and frequency (,29 mT vs. 40 mT,
187 kHz vs. 183 kHz) as well as intrinsic magnetic properties of
MSR-1 MNs, could be hypothesized as sources of differences
against the results described in the literature.
However, we showed a local effect of MNs within tumors, with
evidences of tissue necrosis both by histology and MRI
(Figures 8-9). Furthermore, longitudinal MRI data demonstrat-
ed that MNs spread from the injection site through the
surrounding tissue (Figure 8A g, h).
The physiological conditions for MNs migration still need to be
clarified; a possible scenario involves the combination of passive
transport mediated by reticuloendothelial system and active
transport, mediated by macrophages. These processes resemble
the transport pathways for conventional iron oxide nanoparticles,
as described in [31].
The proposed experimental design, that involves both in vitro
and in vivo examination, allows for non invasive follow up of the
lesions at different time points. In addition, our results demon-
strate that clinical MRI could be included in protocols based on
theranostic employment of MNs: both the injection site and the
necrotic areas of the tumor can be detected at once in a single
MRI session. Theranostic is a combination of diagnostics and
therapy and our data confirms that MNs exhibit some core
characteristics of the so called ‘‘theranostic agents’’.
Our results do not match data available in the literature; it has
to be noticed that different parameters used for hyperthermia, as
well as different strain of magnetotactic bacteria used to obtain
MNs and a different tumor model, are all features that could lead
to some inconsistencies with previous discoveries. Future efforts
will focus on the optimization of experimental conditions: initial
tumor volume and MNs administration among others, to obtain a
more homogeneous distribution of nanoparticles and improve the
therapeutic effect of MFH based on MNs.
Figure 8. MR Images of representative animals. A) MRI Upper line: animal treated with MNs injection; images acquired before MNs injection (a),
24 h (b), one week (c) and two weeks (d) after MNs injection. Second line: animal treated with MNs injection with AMF; images acquired before MNs
injection (e), 24 h (f), one week (g) and two weeks (h) after MNs injection. Magnetosomes are injected in tumor mass and MRI allows the detection of
injection sites (white stars). B) animal treated with AMF; images acquired before 24 h (i), one week (l) and two weeks (m) after treatment. Control
animal not treated with MNs and AMF; images acquired after two weeks (n).
doi:10.1371/journal.pone.0108959.g008
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Conclusions
This study reports a multimodal approach to assess biological
properties of MNPs extracted from magnetotactic bacteria. A
clearly detectable increase of temperature has been recorded by
exposing MNs to an AMF. In addition, the temperature increase
showed a good linear relation when measured in samples with
increasing concentrations of MNs. When investigated in vivo by
MRI, chains of our MNs are easily detectable if injected directly in
the living tissue due to their iron content. This suggests a possible
use of these nanoparticles as negative contrast agent or magnetic
tracer. This behavior is useful to localize a bolus of MNs injected
in a tumor mass: we were able to visualize the site of injection and
follow the physiological distribution of nanoparticles within the
tumor over time by MR imaging. Moreover, the same modality
allows to record the effect of AMF exposures on tumors at different
time points. Although we did not observe a reduction of tumor
mass, areas of fibrosis and necrosis were visible at microscopic
level.
Multimodal approach is a valuable strategy to characterize
several aspects of MNs. Many more efforts are needed to further
understand key aspects of their interactions with living systems
[32,33,34], both healthy or not, but these results enforce the
hypothesis of a potential, minimally invasive, therapeutic applica-
tion of nanoparticles-based hyperthermia.
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Figure 9. Histological analysis of tumors. In the Panel A-C histology of tumor of the experimental group is showed. Injection site is showed in
Panel A while in Panel B the living tumor area is illustrated. In the Panel C injured tumor area is showed. In Panel E-F histology of first subgroup of the
control group is presented. In Panel G-I histology of second subgroup of the control group is presented and in the Panel L-N is showed the third
subgroup of the control group. The presence of MNs depots is detectable in injection sites (A). MNs are capable to migrate and spread in tumor tissue
causing the formation of fibrotic and necrotic areas (B, C). Scale bars, A-C 60 mm, D-E 300 mm, F and G 120 mm, H-I 60 mm, I 300 mm, M 120 mm, N
60 mm. Legend: m=MNs, n = necrosis and t = tumor.
doi:10.1371/journal.pone.0108959.g009
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